 CAMBRIDGE, Mass., Aug. 17, 2021 GLOBE NEWSWIRE -- Cue Biopharma, Inc. Nasdaq: CUE, a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patients body, provided a business and clinical progress update for the second quarter 2021. 